Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated:  5/2/2016
Trius Investigator 004
mi
from
Los Angeles, CA
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated: 5/2/2016
Trius Investigator 004
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated:  5/2/2016
Trius Investigator Site 002
mi
from
Orange, CA
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated: 5/2/2016
Trius Investigator Site 002
mi
from
Orange, CA
Click here to add this to my saved trials
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated:  5/2/2016
Trius investigator site 170
mi
from
San Diego, CA
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated: 5/2/2016
Trius investigator site 170
mi
from
San Diego, CA
Click here to add this to my saved trials
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated:  5/2/2016
Trius Investigator 005
mi
from
Columbus, OH
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Status: Enrolling
Updated: 5/2/2016
Trius Investigator 005
mi
from
Columbus, OH
Click here to add this to my saved trials
Sexually Transmitted Infections Among African American Women Who Have Sex With Women
Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women
Status: Enrolling
Updated:  5/10/2016
Crossroads Clinic
mi
from
Jackson, MS
Sexually Transmitted Infections Among African American Women Who Have Sex With Women
Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women
Status: Enrolling
Updated: 5/10/2016
Crossroads Clinic
mi
from
Jackson, MS
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Arizona Allergy Associates
mi
from
Chandler, AZ
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Arizona Allergy Associates
mi
from
Chandler, AZ
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Miller Children's Hospital
mi
from
Long Beach, CA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
IMMUNOe International Research Centers
mi
from
Centennial, CO
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
IMMUNOe International Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Allergy Associates of the Palm Beaches, PA
mi
from
N Palm Beach, FL
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Allergy Associates of the Palm Beaches, PA
mi
from
N Palm Beach, FL
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Rush University Medical Center
mi
from
Chicago, IL
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Asthma and Allergy Center
mi
from
Toledo, OH
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Asthma and Allergy Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Dallas Allergy Immunology Research
mi
from
Dallas, TX
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Dallas Allergy Immunology Research
mi
from
Dallas, TX
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
University of Utah / Primary Children's Hospital
mi
from
Salt Lake City, UT
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
University of Utah / Primary Children's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
O&O Alpan
mi
from
Fairfax, VA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Bellingham Asthma, Allergy, & Immunology Clinic
mi
from
Bellingham, WA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Bellingham Asthma, Allergy, & Immunology Clinic
mi
from
Bellingham, WA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Egyesitett Szent Istvan es Szent Laszlo Korhaz
mi
from
Budapest,
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Egyesitett Szent Istvan es Szent Laszlo Korhaz
mi
from
Budapest,
Click here to add this to my saved trials
Does Implementing a Urinanylsis Protocol Based on Symptoms Decrease Length of Stay in the Emergency Department?
A Randomized Controlled Trial Showing the Effect of Patient Lenght of Stay in the Emergency Department Through Utilizing a Urinalysis Nursing Protocol.
Status: Enrolling
Updated:  5/12/2016
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
Does Implementing a Urinanylsis Protocol Based on Symptoms Decrease Length of Stay in the Emergency Department?
A Randomized Controlled Trial Showing the Effect of Patient Lenght of Stay in the Emergency Department Through Utilizing a Urinalysis Nursing Protocol.
Status: Enrolling
Updated: 5/12/2016
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing: Meeting the Needs of an At-Risk Population
Status: Enrolling
Updated:  5/17/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing: Meeting the Needs of an At-Risk Population
Status: Enrolling
Updated: 5/17/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
A Double-Blind, Placebo-Controlled, Single & Multiple Ascending Dose, Safety, Tolerability, & PK Study of an IV Form of TR-701 Free Acid & an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults
Status: Enrolling
Updated:  5/18/2016
Covance Clinical Research Unit
mi
from
Madison, WI
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
A Double-Blind, Placebo-Controlled, Single & Multiple Ascending Dose, Safety, Tolerability, & PK Study of an IV Form of TR-701 Free Acid & an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults
Status: Enrolling
Updated: 5/18/2016
Covance Clinical Research Unit
mi
from
Madison, WI
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center- Pecar
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center- Pecar
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Pecar
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Pecar
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Childrens National Medical Center
mi
from
Washington,
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
University of South Florida School of Medicine
mi
from
Tampa, FL
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
University of South Florida School of Medicine
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Emory Children's Center
mi
from
Atlanta, GA
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Emory Children's Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Louisiana State University Health Science Center-Shreveport
mi
from
Shreveport, LA
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Louisiana State University Health Science Center-Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Washington University in St. Louis, School of Medicine
mi
from
St. Louis, MO
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Washington University in St. Louis, School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Dartmouth Medical School
mi
from
Lebanon, NH
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Dartmouth Medical School
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Steven & Alexandra Cohen Children's Medical Center of New York (CCMC)
mi
from
Manhasset, NY
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Steven & Alexandra Cohen Children's Medical Center of New York (CCMC)
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Carolinas Medical Center - Charlotte
mi
from
Charlotte, NC
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Carolinas Medical Center - Charlotte
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Rhode Island Hospital
mi
from
Providence, RI
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated:  6/6/2016
University of Texas Southwestern
mi
from
Dallas, TX
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Status: Enrolling
Updated: 6/6/2016
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials